GLP-1 Demand and Oligonucleotide Advances Reshape “TIDES” Manufacturing Requirements, Report Finds
Key Points
- Frost & Sullivan and Medtide white paper finds GLP-1 demand driving peptide API capacity, synthesis efficiency and purification needs
- Oligonucleotide advances are expanding beyond rare diseases into cardiovascular and metabolic disorders, raising analytical and scale-up demands
- Report urges evaluating CDMOs for scale-up, raw material sourcing, regulatory experience and flexibility through 2030
Rising demand for GLP-1 medications and expanding applications for oligonucleotide therapeutics are creating new manufacturing challenges for the pharmaceutical industry, according to a new report from Frost & Sullivan and Medtide Inc. The companies have jointly published the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper, examining developments across the peptide and oligonucleotide markets, collectively referred to as TIDES, and the contract development and manufacturing capabilities needed to support these therapies from clinical development through commercial production.
The report identifies different manufacturing priorities for the two therapeutic categories. Growing adoption of GLP-1 treatments for diabetes and obesity is driving demand for peptide active pharmaceutical ingredients (APIs), placing greater emphasis on production capacity, synthesis efficiency and purification capabilities. Meanwhile, improvements in oligonucleotide delivery technologies are opening opportunities beyond rare diseases, with developers increasingly investigating applications in cardiovascular and metabolic disorders. As more candidates progress into late-stage clinical development, manufacturers face growing demands for analytical methods capable of detecting closely related impurities and maintaining product consistency across larger production batches.
These evolving requirements are influencing how pharmaceutical developers evaluate CDMO partnerships throughout the drug development lifecycle. During early-stage development, technical expertise and the ability to resolve manufacturing challenges quickly can help prevent delays as programs advance toward clinical milestones. As products approach commercialization, priorities shift toward proven scale-up capabilities, dependable raw material sourcing and access to manufacturing capacity that can accommodate anticipated market demand.
The report also highlights the importance of regulatory experience and manufacturing flexibility, particularly for companies preparing to launch products across multiple geographic markets. CDMOs that can support regulatory submissions and facilitate technology transfers between manufacturing sites may offer additional advantages as development programs expand.
The white paper provides an overview of the global TIDES CDMO landscape and examines how manufacturers are adapting their operations to meet changing industry requirements. Among the strategies discussed are efforts to qualify alternative raw material suppliers, expand purification capacity and introduce digital batch records to improve manufacturing traceability and documentation.
The report also considers market developments through 2030, providing insight into the manufacturing investments and operational capabilities that will be important as peptide and oligonucleotide pipelines mature.
For drug developers, the findings underscore the need to evaluate manufacturing partners not only on their ability to support current development requirements but also on whether they can accommodate increasing production volumes, evolving analytical demands and future commercial supply commitments.
Learn more at https://hub.frost.com/the-next-wave-of-tides-market-growth-manufacturing-scale-up-and-the-cdmo-industry-outlook/
Total Page Views: 5

















